1. Chaix Baudier M-L, Grudé M, Delagreverie HM, Roussel C, Pere H, Le Guillou-Guillemette H, et al. High prevalence of NNRTI and INI-resistant polymorphic virus in primary HIV infection. Conference on Retroviruses and Opportunistic Infections; 2018; Boston (MA).
2. EACS. EACS guidelines version 9.1. 2018.
http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf
. Accessed 24 Jul 2019.
3. AIDSinfo. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018.
https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
. Accessed 24 Jul 2019.
4. WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. 2018.
https://www.who.int/hiv/pub/guidelines/ARV2018update/en/
. Accessed 24 Jul 2019.
5. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211–20.
https://doi.org/10.1016/S2352-3018(18)30021-3
.